Fig. 1 | Scientific Reports

Fig. 1

From: Low levels of tumor suppressor miR-3619 in plasma contribute to malignant outcomes and a target for nucleic acid therapy in esophageal cancer

Fig. 1

Graphical abstract. In healthy persons, the plasma level of miR-3619-5p are sufficiently supplied. However, as esophageal squamous cell carcinoma (ESCC) progresses, the plasma level of miR-3619‐5p is decreasing. This dynamics of miR-3619‐5p could be the promising biomarker to detect cancer and predict prognoses of ESCC patients. Moreover, the overexpression of miR-3619‐5p suppresses proviral insertion site in Moloney murine leukemia virus 1 (PIM1) expression by inhibiting stability and translation of mRNA. Overexpression of miR-3619‐5p enhances the tumor-killing activity by suppressing PIM1 expression. Low blood levels of miR-3619‐5p are associated with ESCC progression and poor prognoses and could be a target of nucleic acid therapy in ESCC patients.

Back to article page